FRI-2G.309-1-MCDA-08
CHANGES IN CLINICAL-LABORATORY PARAMETERS IN KIDNEY DYSFUNCTION ACCORDING TO THE DEGREE OF IMPAIRMENT OF PATIENTS AT RISK
Abstract
A number of chronic, systemic diseases lead to kidney damage without being primarily renal. Renal diseases do not have specific symptomatology and are most often detected at an advanced stage. Three of the most common causes of chronic kidney disease are diabetic nephropathy, hypertension and diabetes.
A biomarker is defined as an objectively measured characteristic assessed as an indicator of normal biological processes, pathological processes, or response to pharmacological response to therapeutic interventions. For acute or chronic kidney disease, biomarkers must show rapid and reliable changes with disease progression, be specific, sensitive, rapid, and indicate damage to different segments of the nephron.
In this article, we review conventional biomarkers - clinical and laboratory tests such as serum creatinine, proteinuria, glomerular filtration rate, and others - as a tool for early recognition of acute and chronic kidney injury, differential diagnosis, prognosis assessment, treatment response, and functional recovery, divided into four main groups: basic assays, advanced assays, specialized assays and special low molecular weight proteins related to changes in the basic functions of the kidney and the physiological processes occurring in the kidney - filtration, resorption and secretion.
A biomarker is defined as an objectively measured characteristic assessed as an indicator of normal biological processes, pathological processes, or response to pharmacological response to therapeutic interventions. For acute or chronic kidney disease, biomarkers must show rapid and reliable changes with disease progression, be specific, sensitive, rapid, and indicate damage to different segments of the nephron.
In this article, we review conventional biomarkers - clinical and laboratory tests such as serum creatinine, proteinuria, glomerular filtration rate, and others - as a tool for early recognition of acute and chronic kidney injury, differential diagnosis, prognosis assessment, treatment response, and functional recovery, divided into four main groups: basic assays, advanced assays, specialized assays and special low molecular weight proteins related to changes in the basic functions of the kidney and the physiological processes occurring in the kidney - filtration, resorption and secretion.
Keywords
Kidney damage, Kidney dysfunction, Biomarkers
REFERENCES
- Bhowmik, D., Sinha, S., Gupt, A., Tiwari, S. C., & Agarwal, S. K. (2011). Clinical approach to rapidly progressive renal failure. The Journal of the Association of Physicians of India, 59, 38- 41.
- Dias, C. B., Jorge, L. B., Woronik, V., Cavalcante, L. B., & Yu, L. (2022). IgA nephropathy in patients with serum anti-neutrophil cytoplasmic autoantibody (ANCA) positivity: case series. Jornal brasileiro de nefrologia, 44(1), 42-47. https://doi.org/10.1590/2175-8239-JBN-2021-
- García-Estañ, J., & Vargas, F. (2020). Editorial for Special Issue-Biomarkers of Renal Disease. International journal of molecular sciences, 21(21), 8077. https://doi.org/10.3390/ijms21218077
- Kellum, J. A., Bellomo, R., & Ronco, C. (2007). The concept of acute kidney injury and the RIFLE criteria. Contributions to nephrology, 156, 10-16. https://doi.org/10.1159/000102010
- Vanmassenhove, J., Vanholder, R., Nagler, E., & Van Biesen, W. (2013). Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association, 28(2), 254-273. https://doi.org/10.1093/ndt/gfs380
- Wołyniec, W.; Ratkowski, W.; Renke, J.; Renke, M. Changes in Novel AKI Biomarkers after Exercise. A Systematic Review. Int. J. Mol. Sci. 2020, 21, 5673. https://doi.org/10.3390/ijms21165673
- Xie, L., He, J., Liu, X., Tang, S., Wang, W., Li, F., Zhang, Y., Zhang, J., Huang, Y., Zhao, J., Li, Y., & Zhang, J. (2018). Clinical value of systemic symptoms in IgA nephropathy with ANCA positivity. Clinical rheumatology, 37(7), 1953-1961. https://doi.org/10.1007/s10067-017-3931-z